Weight LossResearch

CagriSema Therapy: Complete Guide

CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (GLP-1 agonist), submitted to the FDA for approval in December 2025 with a decision expected in late 2026. In the REDEFINE 1 Phase 3 trial, CagriSema produced 20.4% mean weight loss over 68 weeks — exceeding semaglutide monotherapy by pairing two distinct satiety pathways. It is the first once-weekly amylin + GLP-1 combination targeting obesity.

Typical cost: $400 - $800/month

What is CagriSema?

What Is CagriSema?

CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide (a long-acting amylin receptor agonist) and semaglutide (GLP-1 receptor agonist). Delivered as a single once-weekly subcutaneous injection, CagriSema pairs two distinct satiety pathways — amylin and GLP-1 — to produce greater weight loss than either drug achieves alone.

Why Combine Cagrilintide and Semaglutide?

GLP-1 agonists act primarily through the hypothalamus and slow gastric emptying. Amylin is a separate pancreatic hormone that promotes satiety through distinct receptors in the area postrema of the brainstem and slows gastric emptying through independent mechanisms. By activating both systems, CagriSema reduces appetite through two non-overlapping signals, and early data suggest this combination may also preserve lean body mass better than GLP-1 monotherapy.

Regulatory Status

Novo Nordisk submitted the CagriSema NDA to the FDA in December 2025, with an FDA decision expected in late 2026 pending standard review. The REDEFINE trial program (REDEFINE 1 for obesity without diabetes, REDEFINE 2 for obesity with T2D) produced the pivotal data underpinning the filing. CagriSema is positioned as Novo's response to tirzepatide's market dominance and to the oncoming retatrutide launch.

How CagriSema Works

Dual-Hormone Satiety Pathway

CagriSema engages two complementary appetite-regulation systems in a single weekly injection.

Semaglutide Component (GLP-1 Receptor Agonism)

Semaglutide activates GLP-1 receptors in the hypothalamic arcuate nucleus, stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. Its effects and safety profile are well characterized through the STEP and SELECT trial programs.

Cagrilintide Component (Amylin Receptor Agonism)

Cagrilintide is a long-acting analog of amylin, the hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema — a brainstem region that regulates meal-ending satiety. Amylin activity also delays gastric emptying through a mechanism distinct from GLP-1. The fatty acid side chain on cagrilintide extends its half-life to support once-weekly dosing, matching semaglutide's schedule.

Complementary Effects

GLP-1 and amylin pathways converge on appetite suppression but operate through different receptor populations and brain regions. This non-redundancy is why combining the two produces larger weight loss than either alone — the effects are additive, not competitive.

Preservation of Lean Mass

Early data suggest that combination amylin + GLP-1 therapy may preserve skeletal muscle better than GLP-1 monotherapy at comparable weight-loss levels. This is an active area of investigation in the REDEFINE program.

Benefits & Uses

Clinical Benefits

Superior weight loss: 20.4% mean body weight reduction in REDEFINE 1 — exceeding semaglutide monotherapy (~15%) in similar populations.
Dual-pathway satiety: Appetite suppression through two non-overlapping mechanisms.
Glycemic control: HbA1c reductions in T2D populations comparable to high-dose GLP-1 monotherapy.
Potentially better lean-mass preservation versus GLP-1 alone — a meaningful consideration for long-term metabolic health.
Once-weekly injection — single device, two active agents.
Cardiovascular markers: Reductions in blood pressure, waist circumference, and triglycerides consistent with the GLP-1 class plus additional amylin-driven benefits.

Clinical Evidence & Research

REDEFINE 1 — Obesity Without Diabetes

Phase 3 trial enrolling over 3,400 adults with obesity or overweight and at least one weight-related comorbidity, randomized to CagriSema, semaglutide alone, cagrilintide alone, or placebo for 68 weeks. Reported in New England Journal of Medicine, 2025. Mean body weight change: −20.4% with CagriSema vs −14.9% with semaglutide, −11.5% with cagrilintide, and −3.0% with placebo.

REDEFINE 2 — Obesity With Type 2 Diabetes

Phase 3 trial in adults with T2D. Weight loss of 13–15% with meaningful HbA1c reductions. The magnitude in T2D is typically smaller than non-diabetic populations across the GLP-1 class.

REDEFINE 3 — Cardiovascular Outcomes

Ongoing large-scale cardiovascular outcomes trial; data expected 2027 and will inform long-term positioning against tirzepatide and retatrutide.

Side Effects & Safety

Common Side Effects

Nausea — very common, particularly during dose escalation; additive from both components.
Vomiting — more common than with semaglutide alone.
Constipation — frequent.
Diarrhea — can occur early in therapy.
Decreased appetite — expected mechanism.
Injection-site reactions — typically mild.

GI Tolerability Considerations

Because CagriSema engages two satiety pathways that both slow gastric emptying, GI side effects can be more pronounced than with GLP-1 monotherapy. Titration in clinical trials is deliberately slower than with semaglutide alone, and experienced clinicians often counsel patients to expect a longer on-ramp.

Class Concerns

Pancreatitis, gallbladder disease with rapid weight loss, heart rate increase, and thyroid C-cell tumor risk (animal-only signal) all apply as with other GLP-1 therapies. Hypoglycemia risk rises when combined with insulin or sulfonylureas.

Dosing & Administration

Clinical Trial Titration

CagriSema is administered as a once-weekly subcutaneous injection. The approved commercial titration schedule will be finalized at FDA approval, but REDEFINE protocols used a 16-week escalation to the 2.4 mg / 2.4 mg maintenance dose:

Weeks 1–4: 0.25 mg cagrilintide / 0.25 mg semaglutide weekly
Weeks 5–8: 0.5 mg / 0.5 mg
Weeks 9–12: 1.0 mg / 1.0 mg
Weeks 13–16: 1.7 mg / 1.7 mg
Week 17+: 2.4 mg / 2.4 mg (maintenance)

Administration

Subcutaneous injection in the abdomen, thigh, or upper arm once weekly. Rotate injection sites to reduce irritation.

Access

CagriSema is not yet FDA approved. It is not legally available by prescription or through compounding pharmacies in the United States. Legitimate access is limited to clinical trial enrollment until FDA approval.

Find CagriSema Providers Near You

Search our directory for qualified providers offering CagriSema therapy. Filter by location, telehealth, and more.

Browse Providers

CagriSema FAQ

Novo Nordisk submitted the NDA in December 2025 with FDA decision expected in late 2026 under standard review.

In REDEFINE 1, CagriSema produced 20.4% mean weight loss vs tirzepatide's ~22.5% in SURMOUNT-1 — a cross-trial comparison that suggests the two are roughly similar, with tirzepatide slightly ahead on average. Head-to-head data has not been published. Individual response varies, and tolerability profiles differ.

No legitimate compounded CagriSema exists. Because the drug is not FDA-approved, it cannot be legally compounded for patient use. Vendors selling "compounded cagrisema" or combined cagrilintide/semaglutide injections are not providing an FDA-regulated product.

CagriSema adds cagrilintide — an amylin receptor agonist — to semaglutide. This engages a second, independent satiety pathway in the brainstem, producing larger weight loss than semaglutide alone and potentially preserving more lean mass.

GI side effects can be modestly more intense because two appetite-suppressing pathways are active simultaneously. Titration is typically slower than with semaglutide alone to mitigate this.